Capone, E.; Lattanzio, R.; Gasparri, F.; Orsini, P.; Rossi, C.; Iacobelli, V.; De Laurenzi, V.; Natali, P.G.; Valsasina, B.; Iacobelli, S.;
et al. EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics 2021, 13, 483.
https://doi.org/10.3390/pharmaceutics13040483
AMA Style
Capone E, Lattanzio R, Gasparri F, Orsini P, Rossi C, Iacobelli V, De Laurenzi V, Natali PG, Valsasina B, Iacobelli S,
et al. EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics. 2021; 13(4):483.
https://doi.org/10.3390/pharmaceutics13040483
Chicago/Turabian Style
Capone, Emily, Rossano Lattanzio, Fabio Gasparri, Paolo Orsini, Cosmo Rossi, Valentina Iacobelli, Vincenzo De Laurenzi, Pier Giorgio Natali, Barbara Valsasina, Stefano Iacobelli,
and et al. 2021. "EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors" Pharmaceutics 13, no. 4: 483.
https://doi.org/10.3390/pharmaceutics13040483
APA Style
Capone, E., Lattanzio, R., Gasparri, F., Orsini, P., Rossi, C., Iacobelli, V., De Laurenzi, V., Natali, P. G., Valsasina, B., Iacobelli, S., & Sala, G.
(2021). EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors. Pharmaceutics, 13(4), 483.
https://doi.org/10.3390/pharmaceutics13040483